Key result
Newer DES improve clinical outcomes over first-generation stents while early BRS increase scaffold thrombosis.
Why the study?
To review the numerous devices and clinical drug-eluting stent and bioresorbable scaffold trials reported by Dutch researchers during the 2010s.
This review highlights the pivotal role of Dutch researchers in the evolution of coronary stent technology, from bare metal stents to newer generation DES and the challenges faced with bioresorbable scaffolds.
Answers are grounded in this paper and cite their sources.
Confirms preference for newer-generation DES in practice; leaves open next-generation scaffold optimization.
Dutch researchers were among the first to perform clinical studies in bare metal coronary stents, the use of which was initially limited by a high incidence of in-stent restenosis. This problem was greatly solved by the introduction of drug-eluting stents (DES). Nevertheless, enthusiasm about first-generation DES was subdued by discussions about a higher risk of very-late stent thrombosis and mortality, which stimulated the development, refinement, and rapid adoption of new DES with more biocompatible durable polymer coatings, biodegradable polymer coatings, or no coating at all. In terms of clinical DES research, the 2010s were characterised by numerous large-scale randomised trials in all-comers and patients with minimal exclusion criteria. Bioresorbable scaffolds (BRS) were developed and investigated. The Igaki-Tamai scaffold without drug elution was clinically tested in the Netherlands in 1999, followed by an everolimus-eluting BRS (Absorb) which showed favourable imaging and clinical results. Afterwards, multiple clinical trials comparing Absorb and its metallic counterpart were performed, revealing an increased rate of scaffold thrombosis during follow-up. Based on these studies, the commercialisation of the device was subsequently halted. Novel technologies are being developed to overcome shortcomings of first-generation BRS. In this narrative review, we look back on numerous devices and on the DES and BRS trials reported by Dutch researchers.
No takes yet. Share an insight, caveat, or question.
Kawashima et al. (2020) conducted a review in Coronary artery disease. Drug-eluting stents (DES) and bioresorbable scaffolds (BRS) was evaluated. Newer-generation drug-eluting stents demonstrated improved clinical outcomes compared to first-generation devices, while first-generation bioresorbable scaffolds showed higher rates of scaffold thrombosis leading to their market withdrawal.
Synapse has enriched 10 related papers. Consider them for comparative context: